Innate immunity and vaccine adjuvants: From concepts to the development of a unique adjuvant system as04 used for the formulation of a human papillomavirus (hpv) vaccine

Current Cancer Therapy Reviews

Volumn 6, Issue 2, 2010, Pages 126-137

  Garçon, Nathalie ^a   Leo, Oberdan ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adjuvant system; Hpv vaccine; Improved vaccines; Mpl

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ALUMINUM; ALUMINUM SALT; AS 04; CAPSID PROTEIN L1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER INCIDENCE; CANCER PREVENTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; FATIGUE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE PAIN; INNATE IMMUNITY; MYALGIA; NONHUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; VIRUS PARTICLE;

EID: 77952914473     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791202574     Document Type: Article

References (89)

1. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13(11): 460-9.
2. Beutler B, Jiang Z, Georgel P, et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24: 353-89.
3. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17(1): 1-14.
4. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007; 27(5): 687-90.
5. Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J Pathol 1931; 34: 267-75.
6. Ramon G. Procédés pour accroître la production des antitoxines. Ann Inst Pasteur 1926; 40: 1-10.
7. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
8. Kjaer SK, van den Brule AJC, Bock JE, et al. Human papillomavirus-the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996; 65(5): 601-6.
9. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world-wide. J Pathol 1999; 189(1): 12-9.
10. de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology 2004; 324(1): 17-27.
11. Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochem Soc Trans 2007; 35(Pt 6): 1456-60.
12. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55(4): 244-65.
13. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6(4): 204.
14. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111(2): 278-85.
15. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(Suppl 1): S16-S24.
16. Trottier H, Mahmud S, Lindsay L, Wieting S, Jenkins D, Franco EL. Risk of cervical lesions following incident human papillomavirus infection in young women without evidence of prior exposure. 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3-9, 2007.
17. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl 3): S3-1-S3/10.
18. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992; 23(2): 117-28.
19. de Gruijl TD, Bontkes HJ, Walboomers JMM, et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998; 58(8): 1700-6.
20. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006; 24(Suppl 3): S3-106-S3/113.
21. + regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007; 104(29): 12087-92.
22. Bontkes HJ, de Gruijl TD, Walboomers JMM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999; 80(Pt 2): 409-17.
23. Passmore J-AS, Marais DJ, Sampson C, et al. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia. J Med Virol 2007; 79(9): 1375-80.
24. Rocha-Zavaleta L, Pereira-Suarez AL, Yescas G, Cruz-Mimiaga RM, Garcia-Carranca A, Cruz-Talonia F. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology. Viral Immunol 2003; 16(2): 159-68.
25. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181(6): 1911-9.
26. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9(6): 347-56.
27. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110(3 Suppl 1): S1-10.
28. Christensen ND, Hopfl R, DiAngelo SL, et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75 (Pt 9): 2271-6.
29. Hagensee ME, Olson NH, Baker TS, Galloway DA. Threedimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 1994; 68(7): 4503-5.
30. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75(Pt 8): 2075-9.
31. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89(24): 12180-4.
32. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69(6): 3959-63.
33. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70(2): 960-5.
34. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13(16): 1509-14.
35. Kirnbauer R, Chandrachud LM, O'Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219(1): 37-44.
36. Lin Y-L, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992; 187(2): 612-9.
37. Suzich JA, Ghim S-J, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92(25): 11553-7.
38. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95(15): 1128-37.
39. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2(4): 343-7.
40. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13(2): 324-7.
41. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298(5601): 2199-202.
42. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003; 21(Suppl 2): S2-35-S2/37.
43. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2001; 19(7-8): 877-85.
44. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4): 783-801.
45. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86(6): 973-83.
46. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388(6640): 394-7.
47. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442(7098): 39-44.
48. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10(2): 417-26.
49. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425(6957): 516-21.
50. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6(5): 723-39.
51. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006; 102(1): 10-5.
52. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002; 20 Suppl 3: S34-S39.
53. Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004; 22(27-28): 3658-68.
54. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005; 23(13): 1588-95.
55. Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Schijns V, O'Hagan D, editors. Immunopotentiators in Modern Vaccines. London Elsevier Academic Press, 2006; pp. 161-77.
56. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453(7198): 1122-6.
57. Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opinion Immunol 2009; 21(1): 23-9.
58. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007; 178(8): 5271-6.
59. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9(4): 287-93.
60. Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004; 4(7): 1129-38.
61. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65(20): 3231-40.
62. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982; 257(19): 11808-15.
63. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165(2): 618-22.
64. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Tolllike receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000; 165(10): 5780-7.
65. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003; 2(2): 219-29.
66. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71(5): 2498-507.
67. Tiberio L, Fletcher L, Eldridge JH, Duncan DD. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 2004; 22(11-12): 1515-23.
68. Tomai MA, Johnson AG. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol Response Mod 1989; 8(6): 625-43.
69. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995; 6: 495-524.
70. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5(10): 987-95.
71. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299(5609): 1033-6.
72. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum Salt- and TLR-4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-97.
73. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24(33-34): 5937-49.
74. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002; 22(4): 340-50.
75. Zacks SL, Fried MW. Hepatitis B and C and renal failure. Infect Dis Clin North Am 2001; 15(3): 877-99.
76. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including prehaemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8(2): 235-47.
77. Kong NCT, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68(5): 2298-303.
78. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6(2): 133-40.
79. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347(21): 1652-61.
80. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374(9706): 1975-85.
81. De Carvalho N, Roteli-Martins C, Teixeira J, et al. Immunogenicity and safety of HPV-16/18 AS04-adjuvanted vaccine up to 7.3y. Abstract presented at: 25th International Papillomavirus Conference and Clinical Workshop,Malmö, Sweden, 8-14 May, 2009.
82. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27(4): 581-7.
83. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686): 301-14.
84. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5(10): 705-19.
85. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5(5); 332-40.
86. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26(11): 979-84.
87. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26(51): 6630-8.
88. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23(30): 3876-86.
89. Wraith DC, Goldman M, Lambert P-H. Vaccination and autoimmune disease: what is the evidence? Lancet 2003; 362(9396): 1659-66.